Publications (109) César Augusto Rodríguez Sánchez publications

filter_list

2025

  1. Exercise in cancer patients: assistance levels and referral pathways—a position statement from the Spanish Society of Medical Oncology

    Clinical and Translational Oncology, Vol. 27, Núm. 1, pp. 108-116

2024

  1. Cáncer de mama

    Oncología clínica (Arán), pp. 203-226

  2. Late recurrence of lobular breast carcinoma presented as gastric metastasis

    Revista espanola de enfermedades digestivas, Vol. 116, Núm. 8, pp. 455-456

  3. Oncología clínica coord.

    Arán

  4. PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2− breast cancer

    Cancer Medicine, Vol. 13, Núm. 17

  5. Real-world clinical scenarios during introduction of trastuzumab biosimilar for HER2-positive breast cancer in the European Union

    Future oncology (London, England), Vol. 20, Núm. 13, pp. 821-832

  6. SEOM 2023 clinical guidelines

    Clinical and Translational Oncology

  7. Safety profile of trastuzumab deruxtecan in advanced breast cancer: Expert opinion on adverse event management

    Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1539-1548

  8. Tratamiento Sistémico del Cáncer (I): Quimioterapia

    Oncología clínica (Arán), pp. 73-87

  9. Tratamiento Sistémico del Cáncer (II): hormonoterapia

    Oncología clínica (Arán), pp. 89-99

  10. Tratamiento Sistémico del Cáncer (III): inmunoterapia y terapias biológicas

    Oncología clínica (Arán), pp. 101-116

  11. Urgencias en oncología

    Oncología clínica (Arán), pp. 129-145

2023

  1. Impact of the 21-Gene Assay in Patients with High-Clinical Risk ER-Positive and HER2-Negative Early Breast Cancer: Results of the KARMA Dx Study

    Cancers, Vol. 15, Núm. 5

  2. Intermediate Molecular Phenotypes to Identify Genetic Markers of Anthracycline-Induced Cardiotoxicity Risk

    Cells, Vol. 12, Núm. 15

2022

  1. Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial

    Breast, Vol. 66, pp. 77-84

2021

  1. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

    Annals of Oncology, Vol. 32, Núm. 10, pp. 1245-1255

  2. Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: Patient-reported outcomes in the PEARL study

    European Journal of Cancer, Vol. 156, pp. 70-82

  3. Value of skin tests for managing allergic hypersensitivity reactions to platinum compounds

    International Journal of Clinical Pharmacy, Vol. 43, Núm. 4, pp. 1123-1127

2020

  1. A collection of three integration-free iPSCs derived from old male and female healthy subjects

    Stem Cell Research, Vol. 42

  2. A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study

    Clinical and Translational Oncology, Vol. 22, Núm. 3, pp. 420-428